Cleo SG Progresses Smoothly with Autoimmune Cancer Drug Research Facility Construction... "Completion Within the Year, Collaboration with Domestic and International Pharmaceutical Companies"

CreoSG announced on the 29th that the establishment of its own immuno-oncology research center is progressing smoothly. The immuno-oncology research center is scheduled to be established within this year, and CreoSG plans to intensify its anticancer drug development centered around its own research center.

CreoSG plans to focus on developing anticancer drugs targeting breast cancer, colorectal cancer, skin cancer, pancreatic cancer, and others through the new research facility. The company explained that it will collaborate with leading domestic and international bio companies during the immuno-oncology drug development process.

CreoSG is expanding the application fields of its proprietary vaccine development platform ‘SUV-MAP’ and is advancing it into a platform specialized for immuno-oncology. Based on the advanced SUV-MAP, the company plans to directly administer its own ‘recombinant vesicular stomatitis virus (rVSV)’ into tumor tissues to maximize immune response. CreoSG intends to strengthen its new drug development capabilities not only for efficacy but also to facilitate pipeline expansion into various anticancer drugs in the future.

A CreoSG official stated, "We will complete the establishment of research facilities optimized for the vaccine development technology possessed by CreoSG within this year, and actively proceed with anticancer drug development by additionally recruiting experts in the field of immuno-oncology," adding, "In the future, we will secure an independent research building and expand it to a scale capable of conducting various research including vaccines and anticancer drugs."

He continued, “We will conduct additional research on vectors for vaccines and immuno-oncology drugs and strengthen immuno-oncology drug development capabilities through the advancement of the vaccine platform led by Dr. Son Ho-seon, an immuno-oncology expert recently recruited,” and said, “Pipeline diversification is possible when developing new drugs based on SUV-MAP, and we will secure mid- to long-term growth engines by developing various anticancer drugs.”

Immuno-oncology drugs are considered a highly marketable field among new drugs. According to the global market research firm Grand View Research, the global market size related to immuno-oncology drugs is expected to grow from $136.1 billion (approximately 189 trillion KRW) this year at an average annual growth rate of 8.3% to reach $219.6 billion (approximately 305 trillion KRW) by 2030.

This content was produced with the assistance of AI translation services.